CSIMarket
 


Dyne Therapeutics Inc   (DYN)
Other Ticker:  
 
 

DYN's Operating Income Growth by Quarter and Year

Dyne Therapeutics Inc 's Operating Income results by quarter and year




DYN Operating Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -40.15 -51.96 78.87
III Quarter September -62.27 -42.28 -42.77 -13.52
II Quarter June -66.74 -52.76 -30.17 -239.00
I Quarter March -45.46 -35.78 -25.13 58.00
FY   -174.47 -170.97 -150.03 -115.65



DYN Operating Income third quarter 2023 Y/Y Growth Comment
Dyne Therapeutics Inc in the third quarter 2023 recorded Operating Loss of $ -62.27 millions.

According to the results reported in the third quarter 2023, Dyne Therapeutics Inc achieved the best Operating Income growth in Major Pharmaceutical Preparations industry. While Dyne Therapeutics Inc ' s Operating Income no change of % ranks overall at the positon no. in the third quarter 2023.

Explain Operating Income growth


DYN Operating Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Dyne Therapeutics Inc 's third quarter 2023 Operating Income $ -62.27 millions DYN's Income Statement
Dyne Therapeutics Inc 's third quarter 2022 Operating Income $ -42.28 millions Quarterly DYN's Income Statement
New: More DYN's historic Operating Income Growth >>


DYN Operating Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Operating Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Operating Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Operating Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Dyne Therapeutics Inc 's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


DYN's III. Quarter Q/Q Operating Income Comment
Even if Dyne Therapeutics Inc in the III. Quarter 2023 admitted Operating Loss of $ -62.27 millions, some analyst said, that this are slight up side relative to the -66.74 millions in the second quarter.

Within Major Pharmaceutical Preparations industry Dyne Therapeutics Inc achieved highest sequential Operating Income growth. While Dyne Therapeutics Inc 's Operating Income growth quarter on quarter, overall rank is .


Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


DYN's III. Quarter Q/Q Operating Income Comment
Even if Dyne Therapeutics Inc in the III. Quarter 2023 admitted Operating Loss of $ -62.27 millions, some analyst point out, that current results are slight up side compare to the -66.74 millions in the second quarter.

Within Major Pharmaceutical Preparations industry Dyne Therapeutics Inc achieved highest sequential Operating Income growth. While Dyne Therapeutics Inc 's Operating Income growth quarter on quarter, overall rank is .


Dyne Therapeutics Inc 's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Operating Income 12 Months Ending $ -214.62 $ -194.62 $ -180.64 $ -170.96 $ -182.78
Y / Y Operating Income Growth (TTM) - - - - -
Year on Year Operating Income Growth Overall Ranking # # # # #
Seqeuential Operating Income Change (TTM) - - - - -
Seq. Operating Income Growth (TTM) Overall Ranking # # # # #




Cumulative Operating Income growth Comment
Dyne Therapeutics Inc ' has realized cumulative trailing twelve months Operating Loss of $ -215 millions in the Sep 30 2023 period.
The results are worsening as the cumulative Operating Loss is inflating from $ -194.62 millions in the twelve months ending a quarter before and $ -183.264 millions for the twelve months ending in the quarter a year ago.

Dyne Therapeutics Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Operating Income growth Comment
Dyne Therapeutics Inc ' has realized cumulative trailing twelve months Operating Loss of $ -215 millions in the Sep 30 2023 period.
The business is worsening as the cumulative Operating Loss is becoming larger from $ -194.62 millions in TTM ending quarter Jun 30 2023 and $ -183.264 millions for the twelve months ending in the quarter a year ago Ibai González told.

Dyne Therapeutics Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Operating Income Growth
Major Pharmaceutical Preparations Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
DYN's Operating Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for DYN's Competitors
Operating Income Growth for Dyne Therapeutics Inc 's Suppliers
Operating Income Growth for DYN's Customers

You may also want to know
DYN's Annual Growth Rates DYN's Profitability Ratios DYN's Asset Turnover Ratio DYN's Dividend Growth
DYN's Roe DYN's Valuation Ratios DYN's Financial Strength Ratios DYN's Dividend Payout Ratio
DYN's Roa DYN's Inventory Turnover Ratio DYN's Growth Rates DYN's Dividend Comparisons



Companies with similar Operating Income no change for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Sep 30 2023
Infusystem Holdings Inc79.96%$ 79.958 millions
Elite Pharmaceuticals Inc 78.10%$ 78.103 millions
Amneal Pharmaceuticals Inc 70.56%$ 70.559 millions
Fonar Corporation68.01%$ 68.013 millions
Integer Holdings Corporation64.31%$ 64.314 millions
Cadre Holdings Inc 62.18%$ 62.183 millions
Progyny Inc 61.61%$ 61.608 millions
Neurocrine Biosciences Inc 60.82%$ 60.820 millions
Davita Inc 59.06%$ 59.063 millions
Incyte Corporation55.16%$ 55.161 millions
Cardiff Lexington Corporation51.41%$ 51.406 millions
Lemaitre Vascular Inc 49.27%$ 49.268 millions
Msa Safety Incorporated46.35%$ 46.351 millions
Merck and Co Inc 43.22%$ 43.220 millions
Iradimed Corporation42.91%$ 42.907 millions
Select Medical Holdings Corp42.08%$ 42.084 millions
Semler Scientific Inc 41.01%$ 41.012 millions
Dexcom Inc 39.32%$ 39.322 millions
Ir med Inc 36.64%$ 36.644 millions
Option Care Health Inc 33.48%$ 33.481 millions
Lftd Partners Inc 33.17%$ 33.168 millions
Lantheus Holdings Inc 31.04%$ 31.044 millions
Addus Homecare Corporation30.39%$ 30.389 millions
Third Harmonic Bio Inc 26.30%$ 26.304 millions
Becton Dickinson And Company25.54%$ 25.540 millions
Conmed Corporation24.96%$ 24.959 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com